Efficacy of Murivenna Tail Gudapurana and Yashtimadhu Ghrita Gudapurana in the Postoperative Pain Management of Haemorrhoids and Fissure in-ano: A Research Protocol for a Randomised Controlled Trial

Introduction: Lifestyle diseases resulting from sedentary work, stress, poor sleep, and unhealthy eating habits have led to an increase in anorectal disorders, such as anal fissures, fistulas, haemorrhoids, and abscesses. Haemorrhoids, which are dilated veins in the anal canal, are influenced by factors like prolonged sitting, straining, and pregnancy. Treatment options for haemorrhoids range from laxatives to surgical procedures. In Southern India, Murivenna Tail is commonly used for its antiinflammatory and analgesic properties, aiding in wound healing and postoperative pain management. Need of the study: Surgical procedures for fissure-in-ano, such as Lord’s anal dilatation and lateral internal sphincterotomy, as well as haemorrhoid surgeries including various types of haemorrhoidectomy, can be extremely painful and typically require analgesics for pain management. However, traditional pain relief medications often come with side-effects, including diarrhoea, nausea, vomiting, skin rashes, headaches, mood swings, dependency, and overall dissatisfaction. Murivenna Tail, known for its anti-inflammatory and analgesic properties, presents a cost-effective and readily accessible alternative for managing postoperative pain following fissure and haemorrhoid surgeries. Preclinical studies have shown its potential to reduce inflammation, indicating it could serve as a viable alternative to conventional medications for postoperative pain relief. Aim: To compare the efficacy of Murivenna Tail against Yashitimadhu Ghrita in managing postoperative pain associated with haemorrhoids and fissure-in-ano. Materials and Methods: A randomised controlled trial will be conducted at the Mahatma Gandhi Ayurveda College Hospital and Research Centre (MGACHRC) in Salod, Maharashtra, India, from January 2024 to June 2025. The study will include 72 participants who will provide written informed consent. They will be divided into four groups, with 18 subjects in each group. The treatments administered will be 20 mL of Murivenna Tila and Yashtimadhu Ghrita Gudapuarana, given twice a day for 14 days each. To assess the effectiveness of the four treatment groups Analysis of Variance (ANOVA) will be applied to compare mean scores if the data meet the criteria for normality and homogeneity of variance; otherwise, the Kruskal-Wallis test will be applied.